Author:
Shremo Msdi Abdulwhab,Abdul-Mutakabbir Jacinda C.,Tan Karen K.
Publisher
Springer Science and Business Media LLC
Reference34 articles.
1. Bauer LA. In: Applied clinical pharmacokinetics, 3rd Ed. In: Vancomycin. New York: McGraw-Hill Medical; 2015. Accessed on Jan 21, 2024.
2. Rybak MJ, Le J, Lodise TP, Levine DP, Bradley JS, Liu C, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2020;77(11):835–64.
3. Lodise TP, Drusano GL, Zasowski E, Dihmess A, Lazariu V, Cosler L, et al. Vancomycin exposure in patients with methicillin-resistant Staphylococcus aureus bloodstream infections: how much is enough? Clin Infect Dis. 2014;59(5):666–75.
4. Casapao AM, Lodise TP, Davis SL, Claeys KC, Kullar R, Levine DP, et al. Association between vancomycin day 1 exposure profile and outcomes among patients with methicillin-resistant Staphylococcus aureus infective endocarditis. Antimicrob Agents Chemother. 2015;59(6):2978–85.
5. Timothy J. Bensman PMB. Winter’s basic clinical pharmacokinetics / Paul Beringer, PharmD, Associate Professor, University of Southern California, Los Angeles, CA. . In: Vosburgh MHA, editor. Winter's Basic Clinical Pharmacokinetics Sixth edition. Philadelphia Lippincott Williams & Wilkins, a Wolters Kluwer business 2018.